When will Beam Therapeutics submit a BLA for Risto-cel?
22.0 pts (24h)Health & MedicineOne-OffScience1mois
KalshiVérifier la disponibilitéKYC requis2% de fraisDonnées de résolution vérifiéesAssez bien calibréProbabilité implicite actuelle
before April 2027 93%En tête parmi 6 options
Qualité du marché
44 / 100
Faible qualitéVolume 24h
1 k €
Liquidité
16,9 k €
Liquidité moyenneÉcart
84.0 pt
Spread largeDonnées du marché
Mis à jour il y a 3 minutes
24 mars 26, 14:00 UTC1 nov. 26, 05:00 UTC
Tendances
Marchés Associés
Questions liées pour le contexte, et non une comparaison de contrats équivalents.
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
KalshiFDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
KalshiWhen will Compass Pathways submit a NDA for COMP360 psilocybin?
KalshiWill we get AGI before 2029?
Manifold MarketsWill we get AGI before 2028?
Manifold MarketsWill we get room temperature superconductors before 2033?
Manifold MarketsRègles
If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Sep 1, 2026, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Oct 1, 2026, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Nov 1, 2026, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Dec 1, 2026, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Jan 1, 2027, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Apr 1, 2027, then the market resolves to Yes.
Marchés ouverts
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No97%
- Yes3%
- Volume total
- 15,6 M €
- Volume 24h
- 11,6 k €
POLYMARKETNew pandemic in 2026?
- No-1.0pt93.1%
- Yes+1.0pt6.9%
- Volume total
- 921 k €
- Volume 24h
- 4,7 k €
POLYMARKETMeasles cases in U.S. in 2026?
- ↑3.5k100%
- ↑500+0.1pt100%
- ↑1k+0.1pt100%
+9 résultats de plus
KALSHIMedtronic cardiovascular growth in Q2
- Above 8%92%
- Above 9%81%
- Above 11%45%
+6 résultats de plus
- Volume total
- 2,6 k €
- Volume 24h
- 1,4 k €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-1.0pt60%
+2 résultats de plus
- Volume total
- 869,1 k €
- Volume 24h
- 1,3 k €
KALSHIPandemic in 2026?
- No95%
- Yes5%
- Volume total
- 612,8 k €
- Volume 24h
- 1,1 k €
- Cyclosporiasis cases reported in the US in 2026?
- Measles cases in U.S. by September 30?
- What will RFK say during RNC Midterm Convention?
- Will the FDA approve retatrutide?
- What will the average number of measles cases be during Trump's term?
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- Will WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- How many West Nile neuroinvasive disease cases will be reported among New York City residents in 2026?
- Will the FDA approve cytisinicline for smoking cessation?
Questions fréquentes
- Quelles sont les probabilités actuelles pour When will Beam Therapeutics submit a BLA for Risto-cel? ?
- Kalshi cote before April 2027 à 93% au 10 septembre 2026.
- Quand When will Beam Therapeutics submit a BLA for Risto-cel? sera-t-il résolu ?
- When will Beam Therapeutics submit a BLA for Risto-cel? doit être résolu le 1 novembre 2026.
- Comment When will Beam Therapeutics submit a BLA for Risto-cel? est-il réglé ?
- Kalshi règle ce marché comme suit : If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Sep 1, 2026, then the market resolves to Yes.